James Nam

Younger age and higher body mass index may be positive predictors of progression-free survival in patients with squamous cell carcinoma of the lung.

Adjuvant chemotherapy administered prior to, rather than concurrently with, radiotherapy improves survival outcomes among patients with NSCLC.

More than 50% of patients report experiencing cancer-related fatigue throughout the disease process.

Results of two phase 3 studies found that nivolumab provided superior overall survival vs docetaxel in people with non-small cell lung cancer.

Trial results provided strong evidence against the use of anticoagulant low molecular weight heparin in SCLC.

Patients with NSCLC experienced improvements in both function and quality of life with yoga therapy.

Study results stress the importance of a multiethnic support system for patients needing to overcome communication barriers.

PanCan study effectively identified patients who eventually developed early-stage lung cancer, compared to other predictive models.

Pazopanib improves progression-free survival in patients with small-cell lung cancer.

First generation EGFR tyrosine kinase inhibitors should be used in combination with chemotherapy if a patient has progressive EGFR mutation-positive non-small cell lung cancer.

There may be a decreased rate of lung cancer for patients who receive anti-inflammatory therapy with canakinumab.

Bevacizumab-awwb was approved based on pharmacokinetic and pharmacodynaic profiles and immunogenicity, safety, and efficacy data.

Data from 5 phase 2/3 studies demonstrate improved weight and body mass in patients with NSCLC receiving anamorelin.

A retrospective study of lung cancer clinical trials found that trials continue to increase their eligibility criteria, creating barriers to patient access.

Priority review for alectinib was granted based on evidence from the phase 3 ALEX and J-ALEX clinical trials.

Durvalumab can be used to treat patients with locally advanced, unrescetable NSCLC, who do not relapse after platinum-based chemoradiation.

Patients who underwent lung CT screening had a higher 2-week smoking cessation rate vs patients who did not undergo screening.